APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Haemophilus Influenzae Type B Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Haemophilus Influenzae Type B Vaccine Market Outlook and Growth Opportunities 2026

Report ID 173996700422 December 2025198 pages

Choose your research edition.

Industry ResearchHaemophilus Influenzae Type B Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Haemophilus Influenzae Type B Vaccine Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Haemophilus Influenzae Type B Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Haemophilus Influenzae Type B Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Haemophilus Influenzae Type B Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Haemophilus Influenzae Type B Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Haemophilus Influenzae Type B Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Haemophilus Influenzae Type B Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Haemophilus Influenzae Type B Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Haemophilus Influenzae Type B Vaccine market include Takeda Pharmaceuticals Company, Sanofi, Novartis, Merck, Lanzhou Institute of Biologica, GlaxoSmithKline, Walvax Biotechnology and Immunize BC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Haemophilus Influenzae Type B Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Haemophilus Influenzae Type B Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Haemophilus Influenzae Type B Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Haemophilus Influenzae Type B Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Haemophilus Influenzae Type B Vaccine Segment by Company

Takeda Pharmaceuticals Company

Sanofi

Novartis

Merck

Lanzhou Institute of Biologica

GlaxoSmithKline

Walvax Biotechnology

Immunize BC

Haemophilus Influenzae Type B Vaccine Segment by Type

Liquid Combination HIB

Liquid Monovalent HIB

Lyophilized Combination HIB

Lyophilized Monovalent HIB

Haemophilus Influenzae Type B Vaccine Segment by Application

Pharmaceutical and Biotechnology Companies

Hospital

Research Institutions

Academic Institutions

Other

Haemophilus Influenzae Type B Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Haemophilus Influenzae Type B Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Haemophilus Influenzae Type B Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Haemophilus Influenzae Type B Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Haemophilus Influenzae Type B Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Haemophilus Influenzae Type B Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Haemophilus Influenzae Type B Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Haemophilus Influenzae Type B Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Haemophilus Influenzae Type B Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Haemophilus Influenzae Type B Vaccine industry.

Chapter 3: Detailed analysis of Haemophilus Influenzae Type B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Haemophilus Influenzae Type B Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Haemophilus Influenzae Type B Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Haemophilus Influenzae Type B Vaccine Industry Trends Table 2. Haemophilus Influenzae Type B Vaccine Industry Drivers Table 3. Haemophilus Influenzae Type B Vaccine Industry Opportunities and Challenges Table 4. Haemophilus Influenzae Type B Vaccine Industry Restraints Table 5. Global Haemophilus Influenzae Type B Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Haemophilus Influenzae Type B Vaccine Revenue Share by Company (2021-2026) Table 7. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Haemophilus Influenzae Type B Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Haemophilus Influenzae Type B Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Haemophilus Influenzae Type B Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Haemophilus Influenzae Type B Vaccine Company, Product Type & Application Table 13. Global Haemophilus Influenzae Type B Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Haemophilus Influenzae Type B Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Liquid Combination HIB Table 18. Significant Companies of Liquid Monovalent HIB Table 19. Significant Companies of Lyophilized Combination HIB Table 20. Significant Companies of Lyophilized Monovalent HIB Table 21. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Type (2021-2026) & (k units) Table 23. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Type (2027-2032) & (k units) Table 24. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Type (2021-2026) Table 25. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Type (2027-2032) Table 26. Global Haemophilus Influenzae Type B Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Haemophilus Influenzae Type B Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Haemophilus Influenzae Type B Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Type (2021-2026) Table 30. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Pharmaceutical and Biotechnology Companies Table 32. Significant Companies of Hospital Table 33. Significant Companies of Research Institutions Table 34. Significant Companies of Academic Institutions Table 35. Significant Companies of Other Table 36. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Application (2021-2026) & (k units) Table 38. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Application (2027-2032) & (k units) Table 39. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Application (2021-2026) Table 40. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Application (2027-2032) Table 41. Global Haemophilus Influenzae Type B Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Haemophilus Influenzae Type B Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Haemophilus Influenzae Type B Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Application (2021-2026) Table 45. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Application (2027-2032) Table 46. Global Haemophilus Influenzae Type B Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Haemophilus Influenzae Type B Vaccine Sales by Region (2021-2026) & (k units) Table 48. Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Region (2021-2026) Table 49. Global Haemophilus Influenzae Type B Vaccine Sales by Region (2027-2032) & (k units) Table 50. Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Region (2027-2032) Table 51. Global Haemophilus Influenzae Type B Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Haemophilus Influenzae Type B Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Region (2021-2026) Table 54. Global Haemophilus Influenzae Type B Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Region (2027-2032) Table 56. Global Haemophilus Influenzae Type B Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Haemophilus Influenzae Type B Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Haemophilus Influenzae Type B Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Haemophilus Influenzae Type B Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Haemophilus Influenzae Type B Vaccine Sales by Country (2021-2026) & (k units) Table 61. Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Country (2021-2026) Table 62. Global Haemophilus Influenzae Type B Vaccine Sales by Country (2027-2032) & (k units) Table 63. Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Country (2027-2032) Table 64. Global Haemophilus Influenzae Type B Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Haemophilus Influenzae Type B Vaccine Sales Value Market Share by Country (2021-2026) Table 66. Global Haemophilus Influenzae Type B Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Haemophilus Influenzae Type B Vaccine Sales Value Market Share by Country (2027-2032) Table 68. Takeda Pharmaceuticals Company Company Information Table 69. Takeda Pharmaceuticals Company Business Overview Table 70. Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Product Portfolio Table 72. Takeda Pharmaceuticals Company Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Haemophilus Influenzae Type B Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Sanofi Haemophilus Influenzae Type B Vaccine Product Portfolio Table 77. Sanofi Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Haemophilus Influenzae Type B Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novartis Haemophilus Influenzae Type B Vaccine Product Portfolio Table 82. Novartis Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Haemophilus Influenzae Type B Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Merck Haemophilus Influenzae Type B Vaccine Product Portfolio Table 87. Merck Recent Development Table 88. Lanzhou Institute of Biologica Company Information Table 89. Lanzhou Institute of Biologica Business Overview Table 90. Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Product Portfolio Table 92. Lanzhou Institute of Biologica Recent Development Table 93. GlaxoSmithKline Company Information Table 94. GlaxoSmithKline Business Overview Table 95. GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Product Portfolio Table 97. GlaxoSmithKline Recent Development Table 98. Walvax Biotechnology Company Information Table 99. Walvax Biotechnology Business Overview Table 100. Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Product Portfolio Table 102. Walvax Biotechnology Recent Development Table 103. Immunize BC Company Information Table 104. Immunize BC Business Overview Table 105. Immunize BC Haemophilus Influenzae Type B Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Immunize BC Haemophilus Influenzae Type B Vaccine Product Portfolio Table 107. Immunize BC Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Haemophilus Influenzae Type B Vaccine Distributors List Table 111. Haemophilus Influenzae Type B Vaccine Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Haemophilus Influenzae Type B Vaccine Product Image Figure 2. Global Haemophilus Influenzae Type B Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Haemophilus Influenzae Type B Vaccine Sales (2021-2032) & (k units) Figure 5. Global Haemophilus Influenzae Type B Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Haemophilus Influenzae Type B Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Liquid Combination HIB Image Figure 10. Liquid Monovalent HIB Image Figure 11. Lyophilized Combination HIB Image Figure 12. Lyophilized Monovalent HIB Image Figure 13. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Type (2021-2032) Figure 16. Global Haemophilus Influenzae Type B Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Haemophilus Influenzae Type B Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Type (2021-2032) Figure 19. Pharmaceutical and Biotechnology Companies Image Figure 20. Hospital Image Figure 21. Research Institutions Image Figure 22. Academic Institutions Image Figure 23. Other Image Figure 24. Global Haemophilus Influenzae Type B Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Application (2021-2032) Figure 27. Global Haemophilus Influenzae Type B Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Haemophilus Influenzae Type B Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Application (2021-2032) Figure 30. Global Haemophilus Influenzae Type B Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Haemophilus Influenzae Type B Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. North America Haemophilus Influenzae Type B Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Haemophilus Influenzae Type B Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Haemophilus Influenzae Type B Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032) & (US$ Million) Figure 41. South America Haemophilus Influenzae Type B Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Haemophilus Influenzae Type B Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Haemophilus Influenzae Type B Vaccine Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Haemophilus Influenzae Type B Vaccine Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid Combination HIB
  • Liquid Monovalent HIB
  • Lyophilized Combination HIB
  • Lyophilized Monovalent HIB
Applications
  • Pharmaceutical and Biotechnology Companies
  • Hospital
  • Research Institutions
  • Academic Institutions
  • Other
Companies covered
  • Takeda Pharmaceuticals Company
  • Sanofi
  • Novartis
  • Merck
  • Lanzhou Institute of Biologica
  • GlaxoSmithKline
  • Walvax Biotechnology
  • Immunize BC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Haemophilus Influenzae Type B Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Haemophilus Influenzae Type B Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Haemophilus Influenzae Type B Vaccine Market Dynamics
  1. 2.1 Haemophilus Influenzae Type B Vaccine Industry Trends
  2. 2.2 Haemophilus Influenzae Type B Vaccine Industry Drivers
  3. 2.3 Haemophilus Influenzae Type B Vaccine Industry Opportunities and Challenges
  4. 2.4 Haemophilus Influenzae Type B Vaccine Industry Restraints
3 Haemophilus Influenzae Type B Vaccine Market by Company
  1. 3.1 Global Haemophilus Influenzae Type B Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Haemophilus Influenzae Type B Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Haemophilus Influenzae Type B Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Haemophilus Influenzae Type B Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Haemophilus Influenzae Type B Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Haemophilus Influenzae Type B Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Haemophilus Influenzae Type B Vaccine Company Product Type and Application
  8. 3.8 Global Haemophilus Influenzae Type B Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Haemophilus Influenzae Type B Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Haemophilus Influenzae Type B Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Haemophilus Influenzae Type B Vaccine Market by Type
  1. 4.1 Haemophilus Influenzae Type B Vaccine Type Introduction
  2. 4.1.1 Liquid Combination HIB
  3. 4.1.2 Liquid Monovalent HIB
  4. 4.1.3 Lyophilized Combination HIB
  5. 4.1.4 Lyophilized Monovalent HIB
  6. 4.2 Global Haemophilus Influenzae Type B Vaccine Sales Volume by Type
  7. 4.2.1 Global Haemophilus Influenzae Type B Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Haemophilus Influenzae Type B Vaccine Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Haemophilus Influenzae Type B Vaccine Sales Value by Type
  11. 4.3.1 Global Haemophilus Influenzae Type B Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Haemophilus Influenzae Type B Vaccine Sales Value by Type (2021-2032)
  13. 4.3.3 Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Type (2021-2032)
5 Haemophilus Influenzae Type B Vaccine Market by Application
  1. 5.1 Haemophilus Influenzae Type B Vaccine Application Introduction
  2. 5.1.1 Pharmaceutical and Biotechnology Companies
  3. 5.1.2 Hospital
  4. 5.1.3 Research Institutions
  5. 5.1.4 Academic Institutions
  6. 5.1.5 Other
  7. 5.2 Global Haemophilus Influenzae Type B Vaccine Sales Volume by Application
  8. 5.2.1 Global Haemophilus Influenzae Type B Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Haemophilus Influenzae Type B Vaccine Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Haemophilus Influenzae Type B Vaccine Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Haemophilus Influenzae Type B Vaccine Sales Value by Application
  12. 5.3.1 Global Haemophilus Influenzae Type B Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Haemophilus Influenzae Type B Vaccine Sales Value by Application (2021-2032)
  14. 5.3.3 Global Haemophilus Influenzae Type B Vaccine Sales Value Share by Application (2021-2032)
6 Haemophilus Influenzae Type B Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Haemophilus Influenzae Type B Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Haemophilus Influenzae Type B Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Haemophilus Influenzae Type B Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Haemophilus Influenzae Type B Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Haemophilus Influenzae Type B Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Haemophilus Influenzae Type B Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Haemophilus Influenzae Type B Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Haemophilus Influenzae Type B Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Haemophilus Influenzae Type B Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Haemophilus Influenzae Type B Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Haemophilus Influenzae Type B Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Haemophilus Influenzae Type B Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Haemophilus Influenzae Type B Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Haemophilus Influenzae Type B Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Haemophilus Influenzae Type B Vaccine Sales Value Share by Country, 2025 VS 2032
7 Haemophilus Influenzae Type B Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Haemophilus Influenzae Type B Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Haemophilus Influenzae Type B Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Haemophilus Influenzae Type B Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Haemophilus Influenzae Type B Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Haemophilus Influenzae Type B Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Haemophilus Influenzae Type B Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Haemophilus Influenzae Type B Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Haemophilus Influenzae Type B Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Haemophilus Influenzae Type B Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Haemophilus Influenzae Type B Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Haemophilus Influenzae Type B Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals Company
  2. 8.1.1 Takeda Pharmaceuticals Company Company Information
  3. 8.1.2 Takeda Pharmaceuticals Company Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Company Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Haemophilus Influenzae Type B Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Haemophilus Influenzae Type B Vaccine Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Haemophilus Influenzae Type B Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Haemophilus Influenzae Type B Vaccine Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Haemophilus Influenzae Type B Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Haemophilus Influenzae Type B Vaccine Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Lanzhou Institute of Biologica
  26. 8.5.1 Lanzhou Institute of Biologica Company Information
  27. 8.5.2 Lanzhou Institute of Biologica Business Overview
  28. 8.5.3 Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Product Portfolio
  30. 8.5.5 Lanzhou Institute of Biologica Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Walvax Biotechnology
  38. 8.7.1 Walvax Biotechnology Company Information
  39. 8.7.2 Walvax Biotechnology Business Overview
  40. 8.7.3 Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Product Portfolio
  42. 8.7.5 Walvax Biotechnology Recent Developments
  43. 8.8 Immunize BC
  44. 8.8.1 Immunize BC Company Information
  45. 8.8.2 Immunize BC Business Overview
  46. 8.8.3 Immunize BC Haemophilus Influenzae Type B Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Immunize BC Haemophilus Influenzae Type B Vaccine Product Portfolio
  48. 8.8.5 Immunize BC Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Haemophilus Influenzae Type B Vaccine Value Chain Analysis
  2. 9.1.1 Haemophilus Influenzae Type B Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Haemophilus Influenzae Type B Vaccine Sales Mode & Process
  6. 9.2 Haemophilus Influenzae Type B Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Haemophilus Influenzae Type B Vaccine Distributors
  9. 9.2.3 Haemophilus Influenzae Type B Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst